Association between Peyronie disease and low serum testosterone levels: Detection and therapeutic considerations

Journal of Andrology

Volumn 33, Issue 3, 2012, Pages 381-388

  Cavallini, Giorgio ^a   Biagiotti, Giulio ^b   Giudice, Cristoforo Lo ^c  

^a Andros Italia   (Italy)

^b Andros Italia   (Italy)

^c Outpatient Clinic of Vicenza   (Italy)

Author keywords

Androgen; Medical therapy

Indexed keywords

ALBUMIN; FOLLITROPIN; LUTEINIZING HORMONE; PLACEBO; PROLACTIN; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; VERAPAMIL;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; FOLLITROPIN BLOOD LEVEL; HUMAN; HUMAN TISSUE; LUTEINIZING HORMONE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; PAIN; PENIS DISEASE; PENIS ERECTION; PENIS PAIN; PEYRONIE DISEASE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; TESTOSTERONE BLOOD LEVEL;

CALCIUM CHANNEL BLOCKERS; HUMANS; MALE; MIDDLE AGED; PAIN; PENILE INDURATION; TESTOSTERONE; TREATMENT OUTCOME; VERAPAMIL;

EID: 84862525047     PISSN: 01963635     EISSN: 19394640     Source Type: Journal    
DOI: 10.2164/jandrol.111.012948     Document Type: Article

References (43)

1. Bassler D, Briel M, Montori VM, Lane M, Glasziou P, et al. Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis. JAMA. 2010;303:1180-1187.
2. Brambilla DJ, Matsumoto AM, Araujo AB, McKinlay JB. The effect of diurnal variation on clinical measurement of serum testosterone and other sex hormone levels in men. J Clin Endocrinol Metab. 2009;94:907-913.
3. Cavallini G. Peyronie's disease: aetiology, pathogenesis and medical therapy. In: Cavallini G, ed. An Updating for Andrology. Kerala, India: Transworld Research Company; 2008:35-58.
4. Cavallini G, Biagiotti G, Koverech A, Vitali G. Oral propionyl-lcarnitine and intraplaque verapamil in the therapy of advanced and resistant Peyronie's disease. BJU Int. 2002;89:895-900.
5. Cavallini G, Modenini F, Vitali G. Open preliminary randomized prospective clinical trial of efficacy and safety of three different verapamil dilutions for intraplaque therapy of Peyronie's disease. Urology. 2007;69:950-954.
6. Chitale S, Morsey M, Swift L, Sethia K. Limited shock wave therapy vs sham treatment in men with Peyronie's disease: results of a prospective randomized controlled double-blind trial. BJU Int. 2010;106:1352-1352.
7. Collier CP, Morales A, Clark A, Lam M, Wynne-Edwards K, Black A. The significance of biological variation in the diagnosis of testosterone deficiency, and consideration of the relevance of total, free and bioavailable testosterone determinations. J Urol. 2010; 183:2294-2299.
8. Crabbe P, Bogaert V, De Bacquer D, Goemaere S, Zmierczak H, Kaufman JM. Part of the interindividual variation in serum testosterone levels in healthy men reflects differences in androgen sensitivity and feedback set point: contribution of the androgen receptor polyglutamine tract polymorphism. J Clin Endocrinol Metab. 2007;92:3604-3610.
9. Elhanbly S, Abdel-Gaber S, Fathy H, El-Bayoumi Y, Wald M, Niederberger CS. Erectile dysfunction in smokers: a penile dynamic and vascular study. J Androl. 2004;25:991-995.
10. Ferrini MG, Rivera S, Moon J, Vernet D, Rajfer J, Gonzalez-Cadavid NF. The genetic inactivation of inducible nitric oxide synthase (iNOS) intensifies fibrosis and oxidative stress in the penile corpora cavernosa in type 1 diabetes. J Sex Med. 2010;7:3033-3044.
11. Ferrini MG, Vernet D, Magee TR, Shahed A, Qian A, Rajfer J, Gonzalez-Cadavid NF. Antifibrotic role of inducible nitric oxide synthase. Nitric Oxide. 2002;6:283-294.
12. Ford LC, King DF, Lagasse LD, Newcomer V. Increased androgen binding in keloids: a preliminary communication. J Dermatol Surg Oncol. 1983;9:545-547.
13. Frajese GV, DeMartinoMU, Calcagni E, Pastore R, Caprio M, Bultrini A, Moretti A. The epidemiology of partial androgen deficiency in aging men (PADAM). J Endocrinol Invest. 2005;28:3-7.
14. Goh VHH, Tong TYY, Mok HPP, Said B. Interactions among age, adiposity, bodyweight, lifestyle factors and sex steroids hormones in healthy Singaporean Chinese men. Asian J Androl. 2007; 9:611-621.
15. Grossmann M. Diagnosis and treatment of hypogonadism in older men: proceed with caution. Asian J Androl. 2010;12:783-786.
16. Hellstrom WJ, Kendirci M, Matern R, Cockerham Y, Myers L, Sikka SC, Venable D, Honig S, McCullough A, Hakim LS, Nehra A, Templeton LE, Pryor JL. Single-blind, multicenter, placebo controlled, parallel study to assess the safety and efficacy of intralesional interferon alpha-2B for minimally invasive treatment for Peyronie's disease. J Urol. 2006;176:394-398.
17. Inal T, Tokatli Z, Akand M, Ozdiler E, Yaman O. Effect of intralesional interferon-alpha 2b combined with oral vitamin E for treatment of early stage Peyronie's disease: a randomized and prospective study. Urology. 2006;67:1038-1042.
18. Karavitakis M, Komninos C, Simaioforidis V, Kontos S, Lefakis G, Politis V, Koritsiadis G, Konstantellou K, Doumanis G. The relationship between androgens, regulators of collagen metabolism, and Peyronie's disease: a case control study. J Sex Med. 2010; 7:4011-4017.
19. Kelâmi A. Autophotography in evaluation of functional penile disorders. Urology. 1983;21:628-629.
20. Lin G, Shindel AW, Banie L, Ning H, Huang YC, Liu G, Lin CS, Lue TF. Pentoxifylline attenuates transforming growth factor-beta1-stimulated elastogenesis in human tunica albuginea-derived fibroblasts part 2: interference in a TGF-beta1/Smad-dependent mechanism and downregulation of AAT1. J Sex Med. 2010;7:1787-1797.
21. Montori VM, Devereaux PJ, Adhikari NK, Burns KE, Eggert CH, Briel M, Lacchetti C, Leung TW, Darling E, Bryant DM, Bucher HC, Schünemann HJ, Meade MO, Cook DJ, Erwin PJ, Sood A, Sood R, Lo B, Thompson CA, Zhou Q, Mills E, Guyatt GH. Randomized trials stopped early for benefit: a systematic review. JAMA. 2005;294:2203-2209.
22. Montorsi F, Adaikan G, Becher E, Giuliano F, Khoury S, et al. Summary of the recommendations on sexual dysfunctions in men. J Sex Med. 2010;7:3572-3588.
23. Moreno SA, Morgentaler A. Testosterone deficiency and Peyronie's disease: pilot data suggesting a significant relationship. J Sex Med. 2009;6:1729-1735.
24. Palmieri A, Imbimbo C, Longo N, Fusco F, Verze P, Mangiapia F, Creta M, Mirone V. A first prospective, randomized, double-blind, placebo-controlled clinical trial evaluating extracorporeal shock wave therapy for the treatment of Peyronie's disease. Eur Urol. 2009;56:363-369.
25. Piao S, Choi MJ, Tumurbaatar M, Kim WJ, Jin HR, Shin SH, Tuvshintur B, Yin GN, Song JS, Kwon MH, Lee SJ, Han JY, Kim SJ, Ryu JK, Suh JK. Transforming growth factor (TGF)-b type I receptor kinase (ALK5) inhibitor alleviates profibrotic TGF-b1 responses in fibroblasts derived from Peyronie's plaque. J Sex Med. 2010;7:3385-3395.
26. Qi W, Gao S, Wang Z. Transcriptional regulation of the TGF-beta1 promoter by androgen receptor. Biochem J. 2008;416:453-462.
27. Rehman J, Benet A, Melman A. Use of intralesional verapamil to dissolve Peyronie's disease plaque: a long-term single-blind study. Urology. 1998;51:620-626.
28. Safarinejad MR, Hosseini SY, Kolahi AA. Comparison of vitamin E and propionyl-L-carnitine, separately or in combination, in patients with early chronic Peyronie's disease: a double-blind, placebo controlled, randomized study. J Urol. 2007;178: 1398-1403.
29. Sartorius G, Ly LP, Sikaris K, McLachlan R, Handelsman DJ. Predictive accuracy and sources of variability in calculated free testosterone estimates. Ann Clin Biochem. 2009;46:137-143.
30. Schaeffer AJ, Burnett AL. Non-surgical interventions for Peyronie disease: 2011 update. J Androl. 2012;33:3-14.
31. Schierle HP, Scholz D, Lemperle G. Elevated levels of testosterone receptors in keloid tissue: an experimental investigation. Plast Reconstr Surg. 1997;100:390-395.
32. Shen ZJ, Zhou XL, Lu YL, Chen ZD. Effect of androgen deprivation on penile ultrastructure. Asian J Androl. 2003;5:33-36.
33. Shirazi M, Haghpanah AR, Badiee M, Afrasiabi MA, Haghpanah S. Effect of intralesional verapamil for treatment of Peyronie's disease: a randomized single-blind, placebo-controlled study. Int Urol Nephrol. 2009;41:467-471.
34. Snedecor GW, Cochran WG. Statistical Methods. 7th ed. Ames: Iowa State University Press; 1987.
35. Sommer F, Schwarzer U, Wassmer G, Bloch W, Braun M, Klotz T, Engelmann U. Epidemiology of Peyronie's disease. Int J Impot Res. 2002;14:379-383.
36. Szardening-Kirchner C, Konrad L, Hauck EW, Haag SM, Eickelberg O, Weidner W. Upregulation of mRNA expression of MCP-1 by TGF-beta1 in fibroblast cells from Peyronie's disease. World J Urol. 2009;27:123-130.
37. Traish A, Kim N. The physiological role of androgens in penile erection: regulation of corpus cavernosum structure and function. J Sex Med. 2005;2:759-770.
38. Tsujita-Kyutoku M, Uehara N, Matsuoka Y, Kyutoku S, Ogawa Y, Tsubura A. Comparison of transforming growth factor-beta/Smad signaling between normal dermal fibroblasts and fibroblasts derived from central and peripheral areas of keloid lesions. In Vivo. 2005;19:959-963.
39. Vermeulen A, Kaufman JM, Giagulli VA. Influence of some biological indexes on sex hormone-binding globulin and androgen levels in aging or obese males. J Clin Endocrinol Metab. 1996;81: 1821-1826.
40. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab. 1999;84:3666-3672.
41. Vernet D, Nolazco G, Cantini L, Magee TR, Qian A, Rajfer J, Gonzalez-Cadavid NF. Evidence that osteogenic progenitor cells in the human tunica albuginea may originate from stem cells: implications for Peyronie disease. Biol Reprod. 2005;73:1199- 1210.
42. Williams JR. The Declaration of Helsinki and public health. Bull WHO. 2008;86:650-652.
43. Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, Oxman AD, Moher D, for the CONSORT and Pragmatic Trials in Healthcare (Practihc) groups. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ. 2008;337:1-8.